These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 15240520

  • 1. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells.
    Shirakawa T, Hamada K, Zhang Z, Okada H, Tagawa M, Kamidono S, Kawabata M, Gotoh A.
    Clin Cancer Res; 2004 Jul 01; 10(13):4342-8. PubMed ID: 15240520
    [Abstract] [Full Text] [Related]

  • 2. Midkine promoter-based conditionally replicative adenovirus for targeting midkine-expressing human bladder cancer model.
    Terao S, Shirakawa T, Kubo S, Bishunu A, Lee SJ, Goda K, Tsukuda M, Hamada K, Tagawa M, Takenaka A, Fujisawa M, Gotoh A.
    Urology; 2007 Nov 01; 70(5):1009-13. PubMed ID: 17919690
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A replication-selective adenoviral vector for head and neck cancers.
    Tanaka H, Shirakawa T, Zhang Z, Hamada K, Gotoh A, Nibu K.
    Arch Otolaryngol Head Neck Surg; 2005 Jul 01; 131(7):630-4. PubMed ID: 16027288
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
    Spinella F, Rosanò L, Di Castro V, Nicotra MR, Natali PG, Bagnato A.
    Clin Cancer Res; 2004 Jul 15; 10(14):4670-9. PubMed ID: 15269139
    [Abstract] [Full Text] [Related]

  • 6. Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells.
    Han S, Inoue H, Flowers LC, Sidell N.
    Clin Cancer Res; 2003 Oct 01; 9(12):4627-35. PubMed ID: 14555539
    [Abstract] [Full Text] [Related]

  • 7. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo.
    Okamoto A, Shirakawa T, Bito T, Shigemura K, Hamada K, Gotoh A, Fujisawa M, Kawabata M.
    Urology; 2008 Jan 01; 71(1):156-60. PubMed ID: 18242386
    [Abstract] [Full Text] [Related]

  • 8. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.
    Zhu HJ, Zhang ZQ, Zeng XF, Wei SS, Zhang ZW, Guo YL.
    Cancer Gene Ther; 2004 Apr 01; 11(4):263-72. PubMed ID: 14963492
    [Abstract] [Full Text] [Related]

  • 9. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
    Taki M, Kagawa S, Nishizaki M, Mizuguchi H, Hayakawa T, Kyo S, Nagai K, Urata Y, Tanaka N, Fujiwara T.
    Oncogene; 2005 Apr 28; 24(19):3130-40. PubMed ID: 15735729
    [Abstract] [Full Text] [Related]

  • 10. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.
    Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, Barker S, Yamaoto M, Li F, Alvarez RD, Curiel DT.
    Cancer Gene Ther; 2004 Apr 28; 11(4):256-62. PubMed ID: 15017380
    [Abstract] [Full Text] [Related]

  • 11. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model.
    Melquist JJ, Kacka M, Li Y, Malaeb BS, Elmore J, Baseman AG, Hsieh JT, Koeneman KS.
    Urol Oncol; 2006 Apr 28; 24(4):362-71. PubMed ID: 16818192
    [Abstract] [Full Text] [Related]

  • 12. Directed apoptosis in Cox-2-overexpressing cancer cells through expression-targeted gene delivery.
    Godbey WT, Atala A.
    Gene Ther; 2003 Aug 28; 10(17):1519-27. PubMed ID: 12900768
    [Abstract] [Full Text] [Related]

  • 13. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
    Latham JP, Searle PF, Mautner V, James ND.
    Cancer Res; 2000 Jan 15; 60(2):334-41. PubMed ID: 10667585
    [Abstract] [Full Text] [Related]

  • 14. [Expression of cyclooxygenase-2 in human transitional cell bladder carcinomas].
    Zhan J, Tang XD.
    Ai Zheng; 2002 Nov 15; 21(11):1212-6. PubMed ID: 12526218
    [Abstract] [Full Text] [Related]

  • 15. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
    Wang R, Wang X, Li B, Lin F, Dong K, Gao P, Zhang HZ.
    Breast Cancer Res Treat; 2009 Sep 15; 117(1):45-54. PubMed ID: 18791823
    [Abstract] [Full Text] [Related]

  • 16. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications.
    Casado E, Gomez-Navarro J, Yamamoto M, Adachi Y, Coolidge CJ, Arafat WO, Barker SD, Wang MH, Mahasreshti PJ, Hemminki A, Gonzalez-Baron M, Barnes MN, Pustilnik TB, Siegal GP, Alvarez RD, Curiel DT.
    Clin Cancer Res; 2001 Aug 15; 7(8):2496-504. PubMed ID: 11489832
    [Abstract] [Full Text] [Related]

  • 17. Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma.
    Wesseling JG, Yamamoto M, Adachi Y, Bosma PJ, van Wijland M, Blackwell JL, Li H, Reynolds PN, Dmitriev I, Vickers SM, Huibregtse K, Curiel DT.
    Cancer Gene Ther; 2001 Dec 15; 8(12):990-6. PubMed ID: 11781662
    [Abstract] [Full Text] [Related]

  • 18. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.
    Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, Rivera AA, Bhoola SM, Barnes MN, Alvarez RD, Curiel DT, Hemminki A.
    J Gene Med; 2003 Apr 15; 5(4):300-10. PubMed ID: 12692864
    [Abstract] [Full Text] [Related]

  • 19. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H, Zhang L, Tang Y, Deisseroth A.
    Cancer Gene Ther; 2003 May 15; 10(5):388-95. PubMed ID: 12719708
    [Abstract] [Full Text] [Related]

  • 20. Cyclooxygenase-2 promotes prostate cancer progression.
    Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimito T, Namiki M, Mizokami A.
    Prostate; 2002 Nov 01; 53(3):232-40. PubMed ID: 12386924
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.